Compare OPBK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.9M | 186.7M |
| IPO Year | 2018 | 2002 |
| Metric | OPBK | KZIA |
|---|---|---|
| Price | $15.21 | $9.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $17.75 | ★ $28.36 |
| AVG Volume (30 Days) | 33.7K | ★ 297.9K |
| Earning Date | 10-22-2026 | 11-06-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $3,204,000.00 | N/A |
| Revenue This Year | $9.47 | N/A |
| Revenue Next Year | $8.78 | N/A |
| P/E Ratio | $14.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $4.86 |
| 52 Week High | $16.83 | $17.40 |
| Indicator | OPBK | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 35.96 |
| Support Level | $14.82 | $9.01 |
| Resistance Level | $15.63 | $14.85 |
| Average True Range (ATR) | 0.26 | 0.70 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 18.40 | 18.83 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.